Minnow Street Minnow Street
Buy Day today: Poor Neutral (54) Good Mixed market breadth · no major macro event

Natures Sunshine Products Inc (NATR)

Consumer Defensive Packaged Foods
20.40 $
Closing price · As of: 24. Jul 2026
🔔 Watch stock
Read the Full Deep Dive
Nature's Sunshine: Five Quarters Above the Estimate — and the Estimate Comes From Two Analysts

Nature's Sunshine Products sells herbal capsules through independent consultants — and has earned more than the market expected five quarters in a row. That is why the stock sits at rank 50 in our Big Earnings Surprise ranking. The filings with the U.S. securities regulator, the SEC, show two things at once: the business really is growing (net sales of $480.1 million in 2025, up 8.5 percent in the first quarter of 2026, all four regions higher) — but little of that reaches the bottom line, because taxes, currencies and a shrinking share count write the second half of the story. Add $84.0 million of cash held abroad, a twelfth of revenue in Russia and Ukraine, and a finance chief who has only been an interim since June 2026. Not investment advice — just a look at who set that bar in the first place.

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Earnings & Surprises
Research

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap
0.4$B
Shares Outstanding
18Mio.
Float
72.2%
Beta
0.9

Performance

Perf. 1M
-1.30%
Perf. 3M
-9.30%
Perf. 6M
-1.30%
YTD Performance (%)
-3.70%
52-Week-High Distance
-26.6%

Valuation

P/E
Forward P/E
16.8
PEG
2.0
P/B
P/S
0.8
EV/EBITDA
7.0
Price/FCF
15.9

Profitability

Gross Margin
72.7%
EBIT Margin
Net Margin
4.1%
Return on Equity
12.4%
Return on Assets
6.8%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
fortress balance sheet
Altman Z
9.61
Piotroski
6 out of 9

Growth

Sales Growth Last Quarter
8.50%
EPS Growth Last Quarter
16.00%
Sales Growth (Year)
5.67%
Forward Sales Growth
4.81%
Forward EPS Growth
0.00%

Quality & Screener

Stage
1
RS Rating
45
EPS Rating
63
Piotroski
6 out of 9
Fundamental Rating
B (+13 out of 100)
fortress balance sheet
Altman Z
9.61

AI Rating

Neutral

In allen sechs ausgewerteten SEC-Berichten (2× 10-K, 4× 10-Q) kommt kein Bezug auf künstliche Intelligenz vor — weder als Umsatzquelle noch als Effizienzhebel noch als Risiko; das Geschäftsmodell ist Herstellung und Direktvertrieb von Nahrungsergänzung.

View the full file — quotes, sources, reviewed filings

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Sales Per Quarter ($M)
2024: Q4 · 118.2 $M Q4 2025: Q1 · 113.2 $M Q1 2025: Q2 · 114.8 $M Q2 2025: Q3 · 128.3 $M Q3 2025: Q4 · 123.8 $M Q4 2026: Q1 · 122.9 $M Q1
Earnings Per Share Per Quarter ($)
2024: Q4 · -0.02 $ Q4 2025: Q1 · 0.27 $ Q1 2025: Q2 · 0.30 $ Q2 2025: Q3 · 0.30 $ Q3 2025: Q4 · 0.23 $ Q4 2026: Q1 · 0.29 $ Q1
Net Margin Per Quarter (%)
2024: Q4 · -0.3 % Q4 2025: Q1 · 4.2 % Q1 2025: Q2 · 4.6 % Q2 2025: Q3 · 4.2 % Q3 2025: Q4 · 3.3 % Q4 2026: Q1 · 4.2 % Q1
Operating Cash Flow Per Quarter ($M)
2024: Q4 · 12.2 $M Q4 2025: Q1 · 2.6 $M Q1 2025: Q2 · 4.3 $M Q2 2025: Q3 · 18.5 $M Q3 2025: Q4 · 9.9 $M Q4 2026: Q1 · -1.8 $M Q1
Free Cash Flow Per Quarter ($M)
2024: Q4 · 10.0 $M Q4 2025: Q1 · 1.5 $M Q1 2025: Q2 · 3.0 $M Q2 2025: Q3 · 16.8 $M Q3 2025: Q4 · 7.6 $M Q4 2026: Q1 · -4.3 $M Q1
Sales Growth vs. Year-Ago Quarter (%)
2024: Q4 · 8.5 % Q4 2025: Q1 · 2.0 % Q1 2025: Q2 · 3.8 % Q2 2025: Q3 · 12.0 % Q3 2025: Q4 · 4.7 % Q4 2026: Q1 · 8.5 % Q1
EPS Growth vs. Year-Ago Quarter (%)
2024: Q4 · -103.6 % Q4 2025: Q1 · 104.5 % Q1 2025: Q2 · 295.3 % Q2 2025: Q3 · 22.7 % Q3 2026: Q1 · 7.8 % Q1
Price Change in Quarter (%)
2024: Q4 · 7.6 % Q4 2025: Q1 · -14.4 % Q1 2025: Q2 · 17.8 % Q2 2025: Q3 · 4.9 % Q3 2025: Q4 · 39.0 % Q4 2026: Q1 · 11.2 % Q1

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.02 -103.60 118 8.50 -0.30 12 10
2025: Q1 0.27 104.50 113 2.00 4.20 3 2
2025: Q2 0.30 295.30 115 3.80 4.60 4 3
2025: Q3 0.30 22.70 128 12.00 4.20 19 17
2025: Q4 0.23 124 4.70 3.30 10 8
2026: Q1 0.29 7.80 123 8.50 4.20 -2 -4
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Assessment: Opportunities & Risks

Growth and market position

Net sales rose 5.7 percent in 2025 to $480.1 million, the highest of the five-year run, and 8.5 percent in the first quarter of 2026 to $122.9 million — in all four regions at once. While the peer group of Herbalife, LifeVantage, Nu Skin and USANA fell from $100 to $25.66 in the annual report's five-year performance table, Nature's Sunshine rose to $152.42 (December 31, 2020 to December 31, 2025).

Balance sheet and funding

At March 31, 2026 equity of $166.9 million stands against total assets of $261.5 million (63.8 percent), plus $87.6 million of cash and an undrawn credit facility ($25.0 million available to July 1, 2027). The caveat: $84.0 million of that cash sits abroad and may be subject to withholding taxes and repatriation restrictions.

Quality of earnings

Little of the operating improvement arrives at the bottom: in the first quarter of 2026 a 54.7 percent gain in operating income translated into only a 7.8 percent gain in net income attributable to common shareholders — a $1.4 million foreign exchange loss and a 37.2 percent effective tax rate in between. On top of that, part of earnings per share comes from the repurchase of 1,260,000 shares in 2025, not from operations.

Business model and dependencies

The operating margin was 5.1 percent in 2025, because 30.1 percent of net sales flows to independent consultants as commission. The 2025 annual report names dependence on a few consultants in individual markets as an explicit risk; Taiwan, the second-largest single market, fell 16.1 percent in the first quarter of 2026.

Regulation and geopolitics

Eastern Europe accounted for $60.0 million of 2025 net sales (12.5 percent of the group) and is still growing. The voluntary self-disclosure over potential U.S. trade control violations was closed by BIS without further action on November 3, 2025, but the disclosure with the sanctions agency OFAC remains pending per the quarterly report for the quarter ended March 31, 2026. The company also expects adverse tariff effects on costs for the remainder of 2026.

Leadership and capital actions

CEO Kenneth Romanzi has been in office since October 29, 2025, and the finance function has been led on an interim basis since June 5, 2026. The 2026 Stock Incentive Plan reserves 1,500,000 shares — 8.5 percent of the count — and passed on May 6, 2026 by a narrow 6,357,245 votes in favor against 5,723,107 opposed, with 1,850,962 abstentions.

Bottom Line

Nature's Sunshine delivers exactly what its label promises — and less than the headline suggests. The business really is growing ($480.1 million of net sales in 2025, up 8.5 percent in the first quarter of 2026, all four regions higher), the balance sheet carries no debt, and against a direct selling industry that has lost three quarters of its value since 2020 the company looks excellent. But the famous streak of five quarters above expectations shrinks in daylight: the bar is set by two analysts, part of earnings per share comes from repurchased stock, and of a 54.7 percent gain in operating income only a 7.8 percent gain in profit survived currency swings and a 37.2 percent tax rate. Add $84.0 million of the $87.6 million cash balance held abroad, a twelfth of revenue in Russia and Ukraine, and an interim finance chief. Not investment advice.

Worth Noting:
  • Nature's Sunshine came onto the research list through the "Big Earnings Surprise" list of our in-house stock scanner: rank 50 of 81 U.S. hits at a relative strength reading of 45, as of July 25, 2026. The lists are recomputed daily, so the ranking is a snapshot.
  • Data basis and scope: annual figures come from the Form 10-K for 2025 filed March 10, 2026; quarterly figures from the Form 10-Q for the quarter ended March 31, 2026, filed May 7, 2026. Filings after May 7, 2026 were reviewed; the material ones are the Form 8-K dated May 11, 2026 (CFO resignation effective June 5, 2026) and the Form S-8 dated May 15, 2026 for the new equity plan. The second quarter 2026 report was not yet available at the time of writing.
  • Not to be confused: Nature's Sunshine Products, Inc. (NATR) has nothing to do with Sunshine Beverages or with Nature's Bounty (part of Nestlé Health Science). Alongside its main brand the company runs the second brand Synergy WorldWide.

About the Company

Nature's Sunshine Products, Inc., ein Unternehmen für natürliche Gesundheit und Wellness, fertigt und verkauft Nahrungsergänzungsmittel und Körperpflegeprodukte in Asien, Europa, Nordamerika, Lateinamerika und international.

Employees806
HeadquartersLehi, UT
Websitenaturessunshine.com
IPO Date25. Jun 2009
Next Earnings30. Jul 2026

Management

Management
Name Title Birth Year
Kenneth G. Romanzi CEO & Director 1960
Daniel C. Norman Executive VP & President of Asia/Pacific (APAC) 1974
L. Shane Jones Executive VP of Finance & Treasurer 1971
Jonathan D. Lanoy SVP, Chief Accounting Ofcr., Principal Accounting Ofcr. & Interim Principal Financial Officer 1975
John Hnanicek Chief Technology Officer
Nathan G. Brower J.D. Executive VP, General Counsel & Secretary 1980
Kevin Fuller Gregory Global Chief Marketing Officer 1971
Jason Roberts Vice President of Global Human Resources
Bryant J. Yates Executive VP and President of Europe & Latin America 1973
Kevin R. Herbert Executive VP & President of North America 1967

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?